ChemoMetec Valuation Multiples

ChemoMetec Overview

About ChemoMetec

ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.

Founded

1997

HQ

Employees

170

Website

chemometec.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $83M

EBITDA: $45M

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

ChemoMetec Financials

ChemoMetec reported last 12-month revenue of $83M and EBITDA of $45M.

In the same LTM period, ChemoMetec generated $70M in gross profit, $45M in EBITDA, and $33M in net income.

ChemoMetec P&L

In the most recent fiscal year, ChemoMetec reported revenue of $78M and EBITDA of $41M.

ChemoMetec expects next 12-month revenue of XXX and NTM EBITDA of XXX

ChemoMetec Stock Performance

ChemoMetec has current market cap of $1B, and enterprise value of $1B.

ChemoMetec's stock price is $62.74.

ChemoMetec Valuation Multiples

ChemoMetec trades at 12.7x EV/Revenue multiple, and 23.5x EV/EBITDA.

ChemoMetec Financial Valuation Multiples

As of March 17, 2026, ChemoMetec has market cap of $1B and EV of $1B.

Equity research analysts estimate ChemoMetec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

ChemoMetec has a P/E ratio of 33.2x.

ChemoMetec Margins & Growth Rates

ChemoMetec's revenue in the last 12 month grew by 17%.

ChemoMetec's revenue per employee in the last FY averaged $0.5M.

ChemoMetec's rule of 40 is 71% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

ChemoMetec's rule of X is 96% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

ChemoMetec Public Comps

See public comps and valuation multiples for other Medical Devices comps.

ChemoMetec M&A Activity

ChemoMetec acquired XXX companies to date.

Last acquisition by ChemoMetec was on XXXXXXXX, XXXXX. ChemoMetec acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

ChemoMetec Investment Activity

ChemoMetec invested in XXX companies to date.

ChemoMetec made its latest investment on XXXXXXXX, XXXXX. ChemoMetec invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).